Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Coronary Artery Disease: HELP
Articles by Roza Badr Eslam
Based on 4 articles published since 2009
(Why 4 articles?)
||||

Between 2009 and 2019, Roza Badr-Eslam wrote the following 4 articles about Coronary Artery Disease.
 
+ Citations + Abstracts
1 Article Usefulness of Intracoronary Brachytherapy for Patients With Resistant Drug-Eluting Stent Restenosis. 2017

Mangione, Fernanda M / Jatene, Tannas / Badr Eslam, Roza / Bergmark, Brian A / Gallagher, Jacob R / Shah, Pinak B / Mauri, Laura / Leopold, Jane A / Sobieszczyk, Piotr S / Faxon, David P / Croce, Kevin J / Bhatt, Deepak L / Devlin, Phillip M. ·Brigham and Women's Hospital Heart & Vascular Center and Harvard Medical School, Boston, Massachusetts; Beneficência Portuguesa de São Paulo Hospital, São Paulo, Brazil. · Brigham and Women's Hospital Heart & Vascular Center and Harvard Medical School, Boston, Massachusetts. · Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria. · Brigham and Women's Hospital Heart & Vascular Center and Harvard Medical School, Boston, Massachusetts. Electronic address: dlbhattmd@post.harvard.edu. ·Am J Cardiol · Pubmed #28583681.

ABSTRACT: In-stent restenosis (ISR) remains a concern even in the drug-eluting stent (DES) era and carries a high risk of recurrence. Brachytherapy is being used as an alternative treatment for resistant ISR, yet the safety and efficacy of this approach has not been well studied. We analyzed the outcomes of 101 patients who underwent coronary brachytherapy for resistant DES ISR. Baseline demographic, clinical, procedural, and outcome data were collected by phone and from electronic records. Comorbidities and overt cardiovascular disease were highly prevalent. Median previous stent layers were 2 with a maximum of 5 layers. Procedural angiographic success rate was 97% and median time to discharge was 1 day after brachytherapy. The primary outcome of target vessel revascularization was 24% at 1 year, 32% at 2 years, and 42% at 3 years. The rate of nonfatal myocardial infarction was 0% at 1 year, 3.5% at 2 years, and 6% at 3 years. The rate of all-cause mortality was 8.5% at 1 year, 12% at 2 years, and 16% at 3 years. We observed only 1 case of late stent thrombosis. After multivariable adjustment, female gender (hazard ratio 2.37, 95% confidence interval 1.02 to 5.52, p = 0.04) and diffuse ISR pattern (hazard ratio 2.95, 95% confidence interval 1.21 to 7.17, p = 0.01) were independently associated with the primary outcome. In conclusion, brachytherapy is feasible for the treatment of resistant DES ISR and is associated with high immediate procedural success and reasonable efficacy in a complex patient population. This approach might be used as an alternative for these patients.

2 Article Clinical presentation and management of stable coronary artery disease in Austria. 2017

Pichlhöfer, Otto / Maier, Manfred / Badr-Eslam, Roza / Ristl, Robin / Zebrowska, Magdalena / Lang, Irene M. ·Department of General Practice and Family Medicine, Centre for Public Health, Medical University of Vienna, Vienna, Austria. · Department of Internal Medicine II, Division of Cardiology, Vienna General Hospital, Medical University of Vienna, Vienna, Austria. · Institute of Medical Statistics, Center for Medical Statistics, Informatics, and Intelligent Systems, Medical University of Vienna, Vienna, Austria. ·PLoS One · Pubmed #28448602.

ABSTRACT: BACKGROUND: Cardiovascular disease is the main cause of death in Austria. However, no systematic information exists regarding characteristics and treatments of contemporary patients with stable coronary artery disease (CAD) in Austria. We assembled two retrospective physicians' databases to describe demographics, clinical profiles, and therapeutic strategies in patients with stable CAD. In addition, we compared patient profiles of secondary care internists and hospital-based cardiologists with those of general practitioners in a primary care setting outside of hospital. METHODS: The study population was identified from retrospective chart review of 1020 patients from 106 primary care physicians in Austria (ProCor II registry), and was merged with a previous similar database of 1280 patients under secondary care (ProCor I registry) to yield a total patient number of 2300. RESULTS: Female patients with stable CAD were older, had more angina and/or heart failure symptoms, and more depression than males. Female gender, type 2 diabetes mellitus, higher CCS class and asthma/COPD were predictors of elevated heart rate, while previous coronary events/revascularization predicted a lower heart rate in multivariate analysis. There were no significant differences with regard to characteristics and management of patients of general practitioners in the primary care setting versus internists in secondary care. CONCLUSIONS: Characteristics and treatments of unselected patients with stable ischemic heart disease in Austria resemble the pattern of large international registries of stable ischemic heart disease, with the exception that diabetes and systemic hypertension were more prevalent.

3 Article Association of thrombin generation potential with platelet PAR-1 regulation and P-selectin expression in patients on dual antiplatelet therapy. 2014

Badr Eslam, Roza / Posch, Florian / Lang, Irene M / Gremmel, Thomas / Eichelberger, Beate / Ay, Cihan / Panzer, Simon. ·Department of Medicine II, Division of Cardiology, Medical University of Vienna, Vienna, Austria. ·J Cardiovasc Transl Res · Pubmed #24435325.

ABSTRACT: We studied the association of thrombin generation potential with platelet protease activated receptor (PAR)-1 regulation and platelet activation in 52 stable coronary artery disease patients on continuous therapy with aspirin and clopidogrel (n = 42) or prasugrel (n = 10). Compared to controls, peak thrombin generation potential was elevated in only 11 patients (p > 0.05), while F1.2 was elevated in 26 patients (p < 0.0001). PAR-1 and thrombin inducible P-selectin expression were significantly elevated in patients compared to controls (p < 0.001). There were no significant correlations between levels of thrombin generation potential or F1.2 and PAR-1 regulation. However, there was a significant inverse correlation between levels of peak thrombin generation potential and in vitro thrombin-inducible expression of P-selectin (p = 0.002), suggesting in vivo depletion of platelet alpha granules due to ongoing platelet activation.

4 Article Human platelet protease-activated receptor-1 responsiveness to thrombin related to P2Y12 inhibition. 2013

Badr Eslam, Roza / Lang, Irene M / Kaider, Alexandra / Panzer, Simon. ·Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria. ·Transl Res · Pubmed #23313628.

ABSTRACT: Dual antiplatelet therapy with aspirin and adenosine diphosphate (ADP) receptor inhibitors significantly improves the outcome of patients with stable coronary heart disease. However, abundant thrombin generation, which is not influenced by this dual antiplatelet therapy, is a major reason for recurrent thromboembolic disease in these patients. We, therefore, assessed in a hypothesis generating study in patients with stable coronary artery disease specifically the relation of responsiveness of the platelet thrombin receptor protease-activated receptor (PAR)-1 to the magnitude of the inhibition of the ADP receptor. PAR-1 regulation was studied prospectively in 86 consecutive patients with stable coronary artery disease treated with aspirin and clopidogrel (67 patients) or prasugrel (19 patients) and correlated the data to ADP inducible platelet reactivity by impedance aggregometry. PAR-1 expression did not differ between patients on aspirin and clopidogrel vs patients on aspirin and prasugrel (P > 0.5). PAR-1 levels were correlated to P-selectin expression (P < 0.0001). The higher the PAR-1 expression the more profound was the in vitro thrombin-inducible platelet activation. However, neither ex vivo PAR-1 expression nor in vitro thrombin-inducible PAR-1 were correlated to ADP-inducible platelet aggregation (P > 0.5). Thus, like in a real life scenario, patients with stable ischemic heart disease on dual antiplatelet therapy may express high levels of PAR-1, which are associated with profound thrombin-inducible platelet activation. This responsiveness cannot be predicted by the magnitude of ADP responsiveness.